Success Metrics

Completion Rate
0%(0/1)
Active Trials
3(75%)
Terminated
1(25%)

Phase Distribution

Ph phase_1
3
75%
Ph phase_3
1
25%

Phase Distribution

3

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 3Large-scale testing
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

3

trials recruiting

Total Trials

4

all time

Status Distribution
Active(3)
Terminated(1)

Detailed Status

Active, not recruiting2
Terminated1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
3
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (75.0%)
Phase 31 (25.0%)

Trials by Status

active_not_recruiting250%
terminated125%
recruiting125%

Recent Activity

3 active trials
Showing 4 of 4
active_not_recruitingphase_1

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma

NCT04246086
recruitingphase_3

Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

NCT06006117
active_not_recruitingphase_1

A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma

NCT03671018
terminatedphase_1

An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma

NCT05315713

Clinical Trials (4)

Showing 4 of 4 trials
NCT04246086Phase 1

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma

Active Not Recruiting
NCT06006117Phase 3

Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Recruiting
NCT03671018Phase 1

A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma

Active Not Recruiting
NCT05315713Phase 1

An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma

Terminated

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4